Compare THRM & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | THRM | SPRY |
|---|---|---|
| Founded | 1991 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 968.2M | 788.5M |
| IPO Year | 1996 | 2020 |
| Metric | THRM | SPRY |
|---|---|---|
| Price | $34.58 | $9.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $37.20 | ★ $40.00 |
| AVG Volume (30 Days) | 209.3K | ★ 1.7M |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $554,979,000.00 | $84,278,000.00 |
| Revenue This Year | $4.96 | $87.40 |
| Revenue Next Year | $7.12 | $81.64 |
| P/E Ratio | $248.43 | ★ N/A |
| Revenue Growth | ★ 50.16 | N/A |
| 52 Week Low | $27.00 | $6.66 |
| 52 Week High | $39.48 | $18.63 |
| Indicator | THRM | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 69.89 | 60.67 |
| Support Level | $32.61 | $7.82 |
| Resistance Level | $34.86 | $9.51 |
| Average True Range (ATR) | 1.02 | 0.61 |
| MACD | 0.42 | 0.14 |
| Stochastic Oscillator | 88.35 | 74.31 |
Gentherm Inc is an automotive parts manufacturer. The business activities of the group function through the Automotive and Medical segments. The vast majority of the firm's revenue comes from the Automotive segment, which includes automotive climate comfort systems, automotive cable systems, battery performance solutions, and automotive electronics and software systems. The medical segment is comprised of the results from the patient temperature management business in the medical industry. Its geographical segments are the USA, China, South Korea, Germany, Japan, the Czech Republic, and other countries.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.